Integra LifeSciences Holdings Corporation (IART) Stake Decreased by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership decreased its position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 40.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 205,264 shares of the life sciences company’s stock after selling 139,387 shares during the period. Artisan Partners Limited Partnership owned about 0.26% of Integra LifeSciences worth $10,362,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Schwab Charles Investment Management Inc. grew its stake in shares of Integra LifeSciences by 9.0% during the third quarter. Schwab Charles Investment Management Inc. now owns 293,774 shares of the life sciences company’s stock valued at $14,830,000 after purchasing an additional 24,218 shares during the last quarter. Legal & General Group Plc grew its stake in shares of Integra LifeSciences by 7.2% during the third quarter. Legal & General Group Plc now owns 125,206 shares of the life sciences company’s stock valued at $6,319,000 after purchasing an additional 8,399 shares during the last quarter. Teachers Retirement System of The State of Kentucky grew its stake in shares of Integra LifeSciences by 85.2% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 35,366 shares of the life sciences company’s stock valued at $1,785,000 after purchasing an additional 16,266 shares during the last quarter. American International Group Inc. grew its stake in shares of Integra LifeSciences by 6.5% during the third quarter. American International Group Inc. now owns 48,997 shares of the life sciences company’s stock valued at $2,473,000 after purchasing an additional 2,994 shares during the last quarter. Finally, Oppenheimer & Co. Inc. grew its stake in shares of Integra LifeSciences by 25.2% during the third quarter. Oppenheimer & Co. Inc. now owns 7,293 shares of the life sciences company’s stock valued at $368,000 after purchasing an additional 1,466 shares during the last quarter. 87.62% of the stock is owned by institutional investors.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ IART) opened at $47.76 on Wednesday. The company has a quick ratio of 3.39, a current ratio of 4.49 and a debt-to-equity ratio of 1.26. The firm has a market cap of $3,790.00, a price-to-earnings ratio of 27.12, a price-to-earnings-growth ratio of 2.15 and a beta of 0.65. Integra LifeSciences Holdings Corporation has a twelve month low of $38.01 and a twelve month high of $56.42.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Thursday, October 26th. The life sciences company reported $0.45 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.47 by ($0.02). The firm had revenue of $278.83 million during the quarter, compared to analyst estimates of $286.00 million. Integra LifeSciences had a return on equity of 16.35% and a net margin of 4.52%. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter last year, the business posted $0.93 earnings per share. sell-side analysts anticipate that Integra LifeSciences Holdings Corporation will post 1.85 EPS for the current year.

In related news, VP Richard D. Gorelick sold 1,500 shares of the firm’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total transaction of $70,785.00. Following the sale, the vice president now directly owns 21,665 shares in the company, valued at $1,022,371.35. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Barbara B. Hill acquired 10,768 shares of the company’s stock in a transaction that occurred on Tuesday, October 31st. The shares were bought at an average price of $46.66 per share, for a total transaction of $502,434.88. Following the completion of the acquisition, the director now owns 55,540 shares of the company’s stock, valued at $2,591,496.40. The disclosure for this purchase can be found here. Company insiders own 21.50% of the company’s stock.

A number of equities analysts have issued reports on the stock. Barclays reaffirmed an “equal weight” rating and issued a $53.00 price objective (up from $47.00) on shares of Integra LifeSciences in a research note on Tuesday, September 12th. Jefferies Group reaffirmed a “buy” rating on shares of Integra LifeSciences in a research note on Sunday, September 10th. Oppenheimer reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Integra LifeSciences in a research note on Monday, September 18th. Zacks Investment Research cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Monday, October 9th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $50.00 price objective (up from $48.00) on shares of Integra LifeSciences in a research note on Thursday, November 9th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $53.82.

COPYRIGHT VIOLATION NOTICE: “Integra LifeSciences Holdings Corporation (IART) Stake Decreased by Artisan Partners Limited Partnership” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://ledgergazette.com/2017/12/06/integra-lifesciences-holdings-corporation-iart-stake-decreased-by-artisan-partners-limited-partnership.html.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply